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Concurrent to conventional bacterial pathogens, unusual microbes are emerging from cystic fibrosis (CF) airways. Nonetheless,
little is known about the contribution of these newly microbes to the resilience of CF-associated biofilms, particularly under
variable-oxygen concentrations that are known to occur in vivo in the mucus of CF patients. Two CF-emergent bacterial species,
Inquilinus limosus and Dolosigranulum pigrum, and the major pathogen Pseudomonas aeruginosa were studied in terms of biofilm
development and antibiotic susceptibilities under in vitro atmospheres with different oxygen availabilities. All species were able to
develop in vitro biofilms under different oxygen-available environments, with D. pigrum accumulating high amounts of biomass
and respiratory activities. When established, biofilms were of difficult eradication, with antibiotics losing their effectiveness in
comparison with the corresponding planktonic populations. Surprisingly, biofilms of each emergent organism displayedmultidrug
resistance under aerobic environments, enduring even in low-oxygen atmospheres. This study suggests a potential prospect on the
impact of nonconventional organisms I. limosus and D. pigrum on CF lung infections, demonstrating capacity to adapt to biofilm
mode of life under restricted-oxygen atmospheres resembling CF airways, which may ultimately endanger the efficacy of currently
used antibiotic regimens.
1. Introduction
Heterogeneous microenvironments are known to occur
within the airways of cystic fibrosis (CF) patients. The pres-
ence of antibiotics, nutrients (e.g., products of inflammatory
cell death, such as DNA and actin polymers), as well as zones
of distinct oxygen tensions, promotes favorable conditions
for bacterial colonization [1], contributing to themultispecies
nature of the infection [2–4]. Arguably, P. aeruginosa is
considered the prevailing pathogen in CF airways, leading to
severe infections that eventually afflict almost all CF patients
and are responsible for the progressive lung injury [5]. P.
aeruginosa is able to grow in the stagnant mucus that is built
up on lung airway epithelia, surviving and adapting into the
anaerobic layers [6, 7] throughout a series of genetic and
phenotypic changes, namely, the formation of biofilms of
difficult eradication [8].
However, it is now known that CF is not amonomicrobial
disease, supporting a wide variety of many uncommon
species [9]. Inquilinus limosus andDolosigranulumpigrum are
two emergent bacteria recently reported in expectorated CF
patients [10]. I. limosus is an aerobic gram-negative bacillus
from the subdivision of 𝛼-Proteobacteria [11] and has been
pointed as a potential threat for CF patients, mainly due
to the mucoid physiology, the multidrug resistance pattern,
and the ability to persist in the respiratory tract [12]. D.
pigrum is a facultative anaerobe that was firstly described
for nearly two decades after being isolated from human
sources [13]. The upper respiratory tract is thought to be
the natural habitat of D. pigrum [14], being associated with
ventilator-associated pneumonia, nosocomial pneumonia,
and septicemia [15, 16]. As for I. limosus, the full pathogenic
potential of D. pigrum in CF remains unclear, with little
information available about its physiological and phenotypic
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features under low-oxygen conditions and even less about its
role in the increasing overall resistance to antibiotic therapy
of CF traditional pathogens. Thus, evaluating the fitness of
uncommon bacteria in in vitro conditions resembling CF
airways may give major insights into their contributions for
CF, being a starting point to determine their potential for
pathogenicity.
As such, this study aimed to investigate the ability of
I. limosus and D. pigrum to develop biofilms and to resist
against several antibiotics under in vitro oxygen environ-
ments (aerobiosis,microaerophilia and anaerobiosis) broadly
representing the microenvironments found in the CF airway
mucus. Results were compared with the performance for P.
aeruginosa.
2. Material and Methods
2.1. Bacterial Strains and Culture Conditions. P. aeruginosa
(wild-type strain UCBPP-PA14), I. limosus (strain M53,
isolated from CF sputum, kindly provided by Dr. Michael
Surette, University of Calgary, AB, Canada), and D. pigrum
(CIP 104051T, Institute Pasteur Collection, Paris, France)
were used throughout this work. All strains were stored
at −70 ± 2∘C in tryptic soy broth (TSB, Liofilchem, Italy)
supplementedwith glycerol. Prior to each assay, bacteria were
subcultured twice from frozen stock preparations onto TSB
supplemented with 1.2% (wt/vol) agar plates and incubated
aerobically at 37∘C for 24–48 h. Pure liquid cultures of P.
aeruginosa and I. limosus were made in TSB whereas D.
pigrum was maintained in brain heart infusion broth (BHI,
Liofilchem, Italy). Tryptic soy agar (i.e., TSB supplemented
with the agar, as described before) was used as culture
medium for CFU countings.
Unless otherwise stated, all rinse steps were performed
either by using 0.9% (wt/vol) saline solution (NaCl; J. T.
Baker, Deventer, The Netherlands) or distilled sterile water.
2.2. Biofilm Growth In Vitro (Biofilm Growth Curves).
Biofilms of each species were formed as previously described
[17], with some modifications. Shortly, cell suspensions
standardized with 1.0 McFarland standards were diluted
in the respective broth medium to achieve ∼107 cells/mL,
dispensed in 96-well microtiter plates, and incubated at 37∘C,
120 rpm, under aerobic, microaerophilic, and anaerobic envi-
ronments. For aerobic assays, microtiter plates were placed
in a standard incubator (n-biotek, Model NB-205Q, Korea).
Microaerophilic biofilms were formed in a microaerophilic
incubator (Thermo Scientific, Forma 311, USA), previously
calibrated with 5% (vol/vol) CO
2
. The anaerobic atmosphere
was created by sealing the plates containing the cell sus-
pensions in plastic boxes with AnaeroGen (Oxoid Limited,
Hampshire, England). Biofilm growth (cultivable cells) was
analyzed every 2 h, until 24 h. At each time point (each 2 h),
the content of the microtiter plates (planktonic fraction)
was discarded and the wells were washed once with sterile
0.9% (wt/vol) saline solution. Biofilms were then detached by
sonication using an ultrasound bath (Sonicor model SC-52,
UK) and cultivable counts were determined on TSA plates,
after aerobic incubation at 37∘C. For each time point, the
old anaerobic generation bag was replaced by a new one,
in order to warrant anaerobic conditions inside the plastic
box. Biofilm growth curves allowed determining the time
needed for biofilms of each species to achieve the threshold
cell concentration interval of 2 × 105 to 2 × 106 CFU/cm2.
Three independent assays were performed for each species
and condition.
2.3. Biofilm Analysis. Microtiter plates containing the
biofilms within the threshold cell concentration of 2 ×
105 to 2 × 106 CFU/cm2 (determined by biofilm growth
curves) were removed from the different incubators, the
wells were washed with saline solution (200𝜇L per well)
after discarding planktonic fraction, and the wells-attached
bacteria were analysed in terms of biomass and respiratory
activity. Wells containing only broth medium were used as
negative controls. All tests were run in three independent
assays.
Biomass. Biomass was quantified by the crystal violet (CV)
staining method, using the procedure previously outlined
[17], with minor modifications. Briefly, wells allowed air
drying for 10min after washing. Attached bacteria were then
fixedwithmethanol (Fisher Scientific, Leicestershire, UK) for
15min and stained with 1% (vol/vol) CV (Merck, Germany)
for 1min. The excess stain was removed by aspirating the
content of each well and washed twice with double-distilled
water. Lastly, wells were decolorized with pure methanol and
the optical density of the obtained solution was measured
at 550 nm (OD
550 nm) using a microtiter plate reader (Model
Sunrise-basic Tecan, Austria).
Metabolic Activity. The metabolic activity of biofilms
was measured using the 2,3-bis(2-methoxy-4-nitro-5-
sulfophenyl)-2H-tetrazolium-5-carboxanilide sodium salt
(XTT) colorimetric method described by Stevens and Olsen
[18], with some modifications. Basically, after biofilm growth
and washing procedures, 200𝜇L of a combined solution of
XTT (Sigma) and phenazine methosulfate (PMS) (Sigma) in
a ratio of 15 : 1 was applied to adhered cells and plates were
incubated at 37∘C for 3 h in the dark. Biofilm activity was
determined through the measurement of the optical density
at 490 nm (OD
490 nm) in each well, using a microtiter plate
reader.
2.4. Antimicrobial Agents. Stock solutions of eight antibi-
otics, tobramycin (Merck, USA), gentamicin, levofloxacin,
ciprofloxacin, clindamycin, cefotaxime, chloramphenicol,
and rifampicin (all from Sigma-Aldrich), were prepared
at 5120mg/L and stored according to the manufacturers’
instructions.
2.5. Planktonic and Biofilm Antibiotic Susceptibilities. The
minimum inhibitory concentrations (MICs) and the min-
imum biofilm eradication concentrations (MBECs) were
determined by adapting the protocol described for the Cal-
gary Biofilm Device (CBD) [19] to the standard microtiter
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plates. Basically, weakly and nonadherent bacteria from
biofilms grown in the microtiter plate wells were removed
by washing the wells with saline solution. Attached bacteria
(biofilms) were then exposed to increasing 2-fold antibiotic
concentrations prepared in cation-adjusted Mueller-Hinton
broth (CAMHB) (for P. aeruginosa and I. limosus) or in
CAMHB supplemented with 5% (vol/vol) sheep blood for
D. pigrum cultures. Microtiter plates were incubated at
37∘C for 24 h, under aerobic, microaerophilic, and anaerobic
environments, as described for biofilm formation. Planktonic
fractions delivered from treated biofilms were transferred
to new microtiter plates and the MICs were obtained by
reading the optical density at 650 nm (OD
650
) for clear wells
(OD
650
< 0.1). The MICs for D. pigrum were determined by
visual observation of the turbidity gradient on the challenge
plate. The remaining biofilms attached to the microtiter plate
wells were rinsed twice with saline solution and disrupted by
sonication (by ultrasound bath), into the appropriate broth
supplemented with 1% (vol/vol) tween 20 (200𝜇L per well).
Disrupted biofilms were then plated onto TSA and incubated
for 37∘C (24–48 h). The MBECs were determined by CFU
counting, being the lowest antibiotic concentration that could
eradicate at least 99% of biofilm-encased cells.
2.6. Statistical Analysis. Data were analyzed using the Prism
software package (GraphPad Software version 5.0 for Mac-
intosh). Biofilm mass and activity were compared by one-
way analysis of variance (ANOVA) and applying the Bon-
ferroni posttest to subsequently compare pairs of columns.
Results were considered statistically significant when 𝑃 <
0.05. Raw data obtained for this paper is available at
http://www.biofomics.org/ [20].
3. Results and Discussion
This study aimed to appraise the adaptation to biofilm
mode of growth of I. limosus and D. pigrum and determine
their respective antibiotic susceptibilities in variable-oxygen
atmospheres resembling CF airways. I. limosus andD. pigrum
are two recently recovered species from the secretions of
CF patients [10, 11]. Unlike P. aeruginosa, which has been
extensively studied in such environments [21–23], no reports
were found to evaluate the performance of such emergent
bacteria while associated with biofilms in the oxygen con-
ditions found in in vivo CF airways. The literature available
so far has only demonstrated their resistance patterns under
standard environments and in planktonic cultures [12, 14],
failing to consider the role of biofilms, of anaerobiosis, and
of polymicrobial infections in CF.
Results revealed that, as for P. aeruginosa, I. limosus
and D. pigrum are able to adapt and survive in variable-
oxygen atmospheres growing as biofilms (Figure 1), showing
high specific growth rates (in orders or magnitude ranging
between 104 and 105 cells/cm2/h). Indeed, the biofilm mode
of growth has been shown to play an important role in
the evolution of bacterial phenotypic diversification, which
is commonly associated with specialized adaptation to the
different compartments in the CF airways [24, 25]. A good
example has been shown for P. aeruginosa, which can survive
for long periods of time under the challenging environment
in CF under these circumstances. The adaptation is clearly
understandable for D. pigrum that, as a facultative anaer-
obe, may more easily thrive under low-oxygen conditions.
Inquilinus genus was initially characterized as aerobic [11],
but the survival of I. limosus isolate under variable-oxygen
tensions in this study might suggest that not all isolates
are necessarily aerobic and may persist under different
oxygen concentration zones within the mucus. Accordingly,
Chiron and colleagues had already detected the presence
of isolates able to survive under both conditions (aerobic
and anaerobic) [12], leading to believe that different strains
may be recovered from different compartments within the
mucus. Additionally, Chiron et al. detected the presence of
strains with nonmucoid and mucoid phenotypes, suggesting
that Inquilinus might be able to undergo a switch to a
mucoid phenotype, leading to biofilm formation and chronic
colonization in CF airways. In this study, we observe that
the CF isolate I. limosus M53 presented a very mucoid
physiology (see Figure S1 in SupplementaryMaterial available
online at http://dx.doi.org/10.1155/2014/678301), which likely
contributed to the slow growth under in vitro conditions and
consequently to the limited biomass and metabolic activity
under the different oxygen concentrations (Figure 2). For
a similar number of CFUs per area of biofilm (ranging
between 2 × 105 and 2 × 106 CFU/cm2), D. pigrum pre-
sented significant values of biomass and respiratory activity
compared with the other species (𝑃 < 0.0001) (Figure 2).
Originally, this observation was supposed to be attributed
to a possibly higher matrix content and cellular activity of
D. pigrum biofilm-encased cells. However, after determining
the biochemical composition of biofilms (Figure S2), it was
observed that the amount of matrix produced by D. pigrum
was not significantly higher than the matrix formed by P.
aeruginosa and I. limosus. This strongly suggests that D.
pigrum biofilm could have more cells, but that those are in a
viable (perceptible in Figure 2(b)) but nonculturable state. As
in this study the number of CFUs before and after antibiotic
application is compared, the fact of having more D. pigrum
cells in the beginning of the experiment (but not CFUs) is
unlikely to affect the final outcome concerning antibiotic
efficacy assessment. P. aeruginosa and I. limosus biofilms
presented similar biomass values in all environments, without
displaying any significant discrepancies (𝑃 > 0.05).The same
tendency was found for the metabolic activity of all biofilms
(Figure 2(b)), with exception for aerobic conditions, where
the classical species was more active than I. limosus.
Because antibiotherapy in CF patients generally targets
only a limited number of microorganisms, in particular
the major pathogen P. aeruginosa [26, 27], disregarding the
impact of other microbes (including emergent) that are
actually present, the antibiotic susceptibilities of I. limosus
and D. pigrum were addressed in this study and compared
with those obtained for P. aeruginosa. Planktonic cells seeded
from treated biofilms served as the inoculum for MIC deter-
minations, which better reflect infections on environmental
settings, including the CF scenarios, where biofilms and
planktonic cells form integrated parts of the microbial
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Figure 1: Growth curves obtained for P. aeruginosa, D. pigrum, and I. limosus single-biofilms growing under aerobic (a), microaerophilic (b),
and anaerobic (c) environments. The means ± standard deviations for three independent assays are illustrated.
lifestyle. Conversely, the standard guidelines, where the
antibiotics are applied to a standard planktonic culture, do
not mirror well what occurs in in vivo CF infections. In
this study, biofilms were highly recalcitrant to most antibi-
otics tested, whereas planktonic cells were in most cases
fully susceptible (Table 1). In fact, these latter populations
(in the planktonic state) seemed to be more sensitive to
most antibiotics than biofilms. Whereas I. limosus plank-
tonic populations did not show significant discrepancies in
antibiotic susceptibilities under the different environments,
the resistances of D. pigrum were noticeably declined under
low- oxygen environments. Aminoglycosides (tobramycin
and gentamicin) and fluoroquinolones (levofloxacin and
ciprofloxacin) presented strong activity (MICs ≤ 2mg/L)
against planktonic P. aeruginosa, whereas for I. limosus only
fluoroquinolones and rifampicin had a strong effect.
TheMICswere not predictive of theMBECs. As expected,
biofilms were notoriously more resistant to antibiotics than
their planktonic counterparts, with MBEC values being, in
general, too much higher than the MICs. There is increased
evidence of enhanced tolerance associated with biofilms,
allowing bacteria to survive, but not necessarily to grow,
in the presence of antibiotic concentrations above their
planktonic MIC [28]. The biofilm mode of growth is the
main reason for the failure of antibiotic treatment to eradicate
airway infection, allowing the bacteria to persist for decades
in the CF lung [29]. Therefore, early treatment strategies
are necessary to prevent or eradicate biofilm formation in
the very early stages, and the maintenance of the inter-
mittent colonization stages becomes crucial as well [30].
Otherwise, mutational resistance mechanisms arise, making
management of the biofilm infection more difficult [29].
Biofilm tolerance is thought to be multifactorial, resulting
from the oxygen and nutrient microscale heterogeneities
within the biofilm; the protective barrier provided by the
exopolysaccharidematrix, restricting or inactivating the pen-
etration of antibiotics into the biofilm; the number and spatial
distribution of bacterial cells within biofilms; the expression
BioMed Research International 5
Table 1: In vitro antibiotic susceptibilities of planktonic and biofilm populations formed by P. aeruginosa (PA), I. limosus (IL), and D. pigrum
(DP) under aerobic, microaerophilic, and anaerobic environments.
Antibiotic Aerobic Microaerophilic Anaerobic
PA IL DP PA IL DP PA IL DP
Tobramycin
MICa ≤2 64 512 ≤2 128 64 ≤2 64 64
MBEC >1024 >1024 >1024 64 >1024 >1024 512 >1024 >1024
Gentamicin
MIC ≤2 8 512 ≤2 16 16 ≤2 16 32
MBEC >1024 >1024 >1024 128 >1024 >1024 1024 >1024 512
Levofloxacin
MIC ≤2 ≤2 512 ≤2 ≤2 16 ≤2 ≤2 16
MBEC >1024 >1024 >1024 256 >1024 >1024 16 >1024 >1024
Ciprofloxacin
MIC ≤2 ≤2 >1024 ≤2 ≤2 16 ≤2 ≤2 32
MBEC 128 >1024 >1024 128 >1024 >1024 128 >1024 >1024
Clindamycin
MIC >1024 16 512 >1024 64 4 >1024 16 4
MBEC >1024 >1024 >1024 >1024 >1024 >1024 >1024 >1024 >1024
Cefotaxime
MIC 128 256 512 32 512 8 32 128 8
MBEC >1024 >1024 >1024 >1024 >1024 >1024 >1024 >1024 >1024
Chloramphenicol
MIC 512 256 256 64 128 8 64 128 16
MBEC >1024 >1024 >1024 >1024 >1024 >1024 >1024 >1024 >1024
Rifampicin
MIC 512 8 1024 >1024 ≤2 ≤2 >1024 ≤2 ≤2
MBEC >1024 256 512 >1024 >1024 >1024 >1024 >1024 64
aMIC and MBEC values are expressed in mg/L.
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Figure 2: Biomass (a) and metabolic activity (b) obtained for single-biofilms formed by P. aeruginosa, I. limosus, and D. pigrum developed
under aerobic, microaerophilic, and anaerobic environments. The means ± standard deviations for three independent assays are illustrated.
∗
𝑃 < 0.05 (one-way ANOVA, Bonferroni’s posttest).
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of biofilm-specific resistance genes; and the presence of
“persisters,” that is, a subpopulation of microorganisms that
differentiate into a dormant but protected state [31, 32].
Interestingly, an increase in antibiotic resistance was
observed for I. limosus and D. pigrum biofilms. This extreme
multidrug tolerance was endured even at oxygen-restricted
conditions, with MBECs being higher than 1024 for at
least 7 from a total of 8 antibiotics. Although the exact
mechanism underlying the high tolerance to antibiotics is
not clearly understood for both organisms, several reasons
are pointed out. For D. pigrum, the high biomass achieved
for these biofilms, associated with the high content of
polysaccharides and proteins leading to a dense extracellular
polymeric matrix (Figure S2), and the number of cells
within the biofilms supposedly to be viable but noncultivable
are suggested to significantly account for that antibiotic
tolerance. In the case of I. limosus, the slimy character of
bacterial colonies is clearly associated with the production
of copious amounts of extracellular polymeric substances. It
is reasonable that the mucoidy of I. limosus may constitute
a physical barrier that limits the permeability of antibiotics
and immobilizes/protects the biofilm-encased cells against
killing. Also, cells buried in this biofilm presented reduced
metabolic activity, making them less susceptible to antibi-
otics, which most (including aminoglycosides and fluoro-
quinolones, commonly used in CF treatment) are known to
primarily target metabolically active biofilm subpopulations
[33].
When extrapolated to the CF scenario, these results
indicate that the presence of emergent bacteria in the CF
airways community may lead to an ineffective antibiotherapy
commonly applied to selected pathogens, worsening lung
symptoms and contributing to the persistence of infection.
Since biofilms have been considered an important pathogenic
trait in CF chronic infections, persisting from years to
decades without possible eradication [34] and assuming that
P. aeruginosa can cause severe biofilm-associated infections,
it is likely that the pathogenic potential of other species not
known to exhibit pathogenic behavior may be measured by
their ability to form biofilms [35–37]. Eventually, these atyp-
ical bacterial species may also interact with the traditional
pathogens, increasing the overall resistance of the consortia
[17]. As such, there is a need to fundamentally address
these latest “holistic” approaches, since the microbe-microbe
and microbe-host interplay within a given ecosystem may
ultimately determine the properties and behaviours of the
overall consortia [9].
In conclusion, although the most common CF pathogen
is P. aeruginosa, this study has evidenced the pronounced
ability of I. limosus and D. pigrum to grow and develop
highly resilient biofilms under oxygen-limited atmospheres.
The ability of emergent bacteria to persist under low-oxygen
environments, resisting to antibiotic treatment, highlights
their chance on the colonization and implication on CF
lung infections. Thus, an adjustment to the actual therapeu-
tic strategies, which are majorly focused on conventional
pathogens, is necessary in face of the complex bacterial
multiplicity and the highly resistant patterns associated with
other than conventional organisms found in CF airways.
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